Page last updated: 2024-10-18

glycine and Leukemia, Myeloid, Acute

glycine has been researched along with Leukemia, Myeloid, Acute in 79 studies

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research Excerpts

ExcerptRelevanceReference
"Ivosidenib 500-mg QD has favorable pharmacokinetic and pharmacodynamic profiles in patients with advanced hematologic malignancies with an IDH1 mutation."9.34Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. ( Agresta, SV; Attar, EC; Dai, D; de Botton, S; DiNardo, CD; Fan, B; Lemieux, I; Liu, G; Liu, H; Stein, E; Yang, H, 2020)
"To the best of our knowledge, this is the first reported case of myopericarditis and cardiogenic shock related to ivosidenib use."9.05Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review. ( Chen, A; Hernandez Burgos, P; Patel, J, 2020)
"We report a case of differentiation syndrome in a patient receiving the IDH1 inhibitor ivosidenib, with skin biopsy showing isocitrate dehydrogenase (IDH) R132H-mutated leukemia cutis."7.96Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. ( Chase, M; Fernandez-Pol, S; Kwong, BY; Novoa, RA; Tabata, MM, 2020)
"Reactive oxygen species (ROS)-specific mechanisms of drug resistance were explored in paraquat (PQ)-resistant acute myelogenous leukemia cell (OCI/AML-2) sublines."7.70Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines. ( Choi, CH; Chung, MH; Jeong, JH; Kim, HS; Kim, MS; Kweon, OS; Lee, TB; Lim, DY; Min, YD; Rha, HS; You, HJ, 2000)
"Ivosidenib 500-mg QD has favorable pharmacokinetic and pharmacodynamic profiles in patients with advanced hematologic malignancies with an IDH1 mutation."5.34Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. ( Agresta, SV; Attar, EC; Dai, D; de Botton, S; DiNardo, CD; Fan, B; Lemieux, I; Liu, G; Liu, H; Stein, E; Yang, H, 2020)
"To the best of our knowledge, this is the first reported case of myopericarditis and cardiogenic shock related to ivosidenib use."5.05Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review. ( Chen, A; Hernandez Burgos, P; Patel, J, 2020)
"We report a case of differentiation syndrome in a patient receiving the IDH1 inhibitor ivosidenib, with skin biopsy showing isocitrate dehydrogenase (IDH) R132H-mutated leukemia cutis."3.96Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. ( Chase, M; Fernandez-Pol, S; Kwong, BY; Novoa, RA; Tabata, MM, 2020)
"The cytotoxic effects of ixazomib treatment were analyzed in human acute myelogenous leukemia (AML) cell lines and primary AML samples expressing wild-type or mutated NPM1 (NPMc(+))."3.83Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species. ( Garcia, JS; Huang, M; Medeiros, BC; Mitchell, BS, 2016)
"Reactive oxygen species (ROS)-specific mechanisms of drug resistance were explored in paraquat (PQ)-resistant acute myelogenous leukemia cell (OCI/AML-2) sublines."3.70Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines. ( Choi, CH; Chung, MH; Jeong, JH; Kim, HS; Kim, MS; Kweon, OS; Lee, TB; Lim, DY; Min, YD; Rha, HS; You, HJ, 2000)
" These findings support the dosing of ivosidenib or enasidenib in combination with intensive chemotherapy for the treatment of patients with newly diagnosed mIDH1/2 AML."3.11Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia. ( Almon, C; Chen, Y; Cooper, M; Fan, B; Hossain, M; Hua, L; Nabhan, S; Yang, H; Yin, F, 2022)
" Given their effectiveness as single agents in mIDH1/2 relapsed or refractory acute myeloid leukemia (AML), this phase 1 study evaluated the safety and efficacy of ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed mIDH1/2 AML."3.01Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. ( Almon, C; Choe, S; Cooper, M; DiNardo, CD; Döhner, H; Fan, B; Fathi, AT; Franovic, A; Frattini, MG; Hua, L; Kantarjian, HM; Lersch, F; Löwenberg, B; McCloskey, JK; Mims, AS; Nabhan, S; Odenike, O; Ossenkoppele, GJ; Patel, PA; Pollyea, DA; Pratz, KW; Roshal, M; Savona, MR; Seet, CS; Stein, AS; Stein, EM; Stone, RM; Tallman, MS; Wang, H; Winer, ES; Wu, B, 2021)
"Ivosidenib is a once daily (q."3.01Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies. ( Fan, B; Jiang, X; Kapsalis, S; Kleijn, HJ; Le, K; Liu, G; Liu, H; Poland, B; Wada, R; Yang, H, 2021)
"Tosedostat is a selective oral aminopeptidase inhibitor, which in phase I/II trials showed acceptable toxicity and encouraging efficacy."3.01A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. ( Ariti, C; Burnett, A; Clark, RE; Copland, M; Dennis, M; Greaves, P; Hemmaway, C; Hills, R; Russell, N; Severinsen, MT; Thomas, I, 2021)
"Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme."2.94Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. ( Agresta, SV; Altman, JK; Arellano, ML; Attar, EC; Choe, S; Dai, D; de Botton, S; DiNardo, CD; Donnellan, W; Erba, HP; Fan, B; Fathi, AT; Hickman, D; Kantarjian, HM; Kapsalis, SM; Liu, H; Mannis, GN; Mims, AS; Pollyea, DA; Prince, GT; Roboz, GJ; Stein, AS; Stein, EM; Stone, RM; Tallman, MS; Uy, GL; Wang, H; Watts, JM; Wu, B; Yen, KE; Zhang, V, 2020)
" A phase I trial of the second-generation proteasome inhibitor ixazomib in combination with MEC (mitoxantrone, etoposide, and cytarabine) was conducted in patients with R/R AML."2.90A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. ( Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W, 2019)
"Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1."2.87Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. ( Agresta, S; Altman, JK; Arellano, ML; Attar, EC; Choe, S; Collins, RH; Dai, D; de Botton, S; DiNardo, CD; Donnellan, W; Erba, HP; Fan, B; Fathi, AT; Foran, JM; Goldwasser, M; Kantarjian, HM; Kapsalis, SM; Liu, H; Mannis, GN; Mims, AS; Pigneux, A; Pollyea, DA; Prince, GT; Roboz, GJ; Sekeres, MA; Slack, JL; Stein, AS; Stein, EM; Stone, RM; Stuart, RK; Swords, R; Tallman, MS; Traer, E; Uy, GL; Wang, H; Willekens, C; Wu, B; Yang, H; Yen, KE; Zhang, V, 2018)
"To identify the maximum-tolerated dose (MTD) and to evaluate the antileukemic activity of tosedostat (formerly CHR-2797), an orally bioavailable aminopeptidase inhibitor."2.75Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. ( Bone, E; Burnett, AK; Davies, F; Dierickx, D; Dührsen, U; Flores, N; Hooftman, L; Jenkins, C; Krug, U; Löwenberg, B; Morgan, G; Müller-Tidow, C; Ossenkoppele, GJ; Richardson, AF; Sonneveld, P; Zachée, P; Zweegman, S, 2010)
"Ivosidenib is a promising, most probably practice changing, new drug for the treatment of IDH1-mutated AML."2.66Evaluating ivosidenib for the treatment of acute myeloid leukemia. ( Donker, ML; Ossenkoppele, GJ, 2020)
"The prognosis of adult acute myeloid leukemia (AML) remains poor, with the long-term survival rate less than 50%."2.61Venetoclax-based therapies for acute myeloid leukemia. ( DiNardo, C; Guerra, VA; Konopleva, M, 2019)
" This orally bioavailable agent has shown promising activity in vitro and in early clinical trials for patients with relapsed/refractory AML."2.50Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. ( Cortes, JE; DiNardo, CD, 2014)
"Acute myeloid leukemia is most often diagnosed in patients older than 60 years of age."2.48Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial. ( Mathisen, MS; Ravandi, F, 2012)
"A majority of patients with acute myeloid leukemia (AML) will relapse after achieving complete remission."2.48The prevalent predicament of relapsed acute myeloid leukemia. ( Szer, J, 2012)
"Ixazomib (IXA) is an orally available proteasome inhibitor, with an improved safety profile compared to Bortezomib (BTZ)."1.62Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. ( Cloos, J; Jansen, G; Kaspers, GJL; Kwidama, ZJ; Roeten, MSF; Segerink, WH; Ter Huizen, G; van Meerloo, J; Zweegman, S, 2021)
"Develop a physiologically based pharmacokinetic (PBPK) model of ivosidenib using in vitro and clinical PK data from healthy participants (HPs), refine it with clinical data on ivosidenib co-administered with itraconazole, and develop a model for patients with acute myeloid leukemia (AML) and apply it to predict ivosidenib drug-drug interactions (DDI)."1.56Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ( Fan, B; Ke, A; Le, K; Prakash, C; Yang, H, 2020)
"Tosedostat is an orally administered metalloenzyme inhibitor with antiproliferative and antiangiogenic activity against hematological and solid human cancers."1.56Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML. ( Candoni, A; Clavio, M; Dennis, M; Giannini, B; Gibellini, D; Gilkes, A; Isidori, A; Loscocco, F; Mianulli, AM; Musuraca, G; Navari, M; Piccaluga, PP; Rocchi, M; Sensi, A; Visani, G; Zuffa, E, 2020)
"Acute and chronic myeloid leukemia are initiated and sustained by a small, self-renewing population of leukemic stem cells, which produce progeny of a heterogeneous population of progenitor cells."1.40Stromal cell derived factor-1 (CXCL12) chemokine gene variant in myeloid leukemias. ( Bahaa, NM; El-Ghany, HM; El-Saadany, ZA; Hussien, SM; Ibrahim, NY, 2014)
"We analyzed 2502 patients with acute myeloid leukemia at diagnosis for NRAS mutations around the hot spots at codons 12, 13, and 61 and correlated the results to cytomorphology, cytogenetics, other molecular markers, and prognostic relevance of these mutations."1.33Implications of NRAS mutations in AML: a study of 2502 patients. ( Bacher, U; Haferlach, T; Kern, W; Schnittger, S; Schoch, C, 2006)
"Two patients of acute myeloblastic leukemia (M2) with post-transfusional hepatitis (non-A, non-B) were treated with alpha-IFN and high-dose SNMC before allogeneic bone marrow transplantation."1.28[Allogeneic bone marrow transplantation after the treatment of alpha-IFN and high-dose SNMC in two cases of acute myeloblastic leukemia with post-transfusional non-A, non-B hepatitis]. ( Fujimoto, H; Fukuhara, T; Hashino, S; Imamura, M; Karino, Y; Kobayashi, H; Matsushima, T; Sakurada, K; Tanaka, M; Yoshida, J, 1989)

Research

Studies (79)

TimeframeStudies, this research(%)All Research%
pre-199013 (16.46)18.7374
1990's0 (0.00)18.2507
2000's2 (2.53)29.6817
2010's27 (34.18)24.3611
2020's37 (46.84)2.80

Authors

AuthorsStudies
Thol, F1
Fan, B9
Chen, Y1
Yin, F1
Hua, L2
Almon, C2
Nabhan, S3
Cooper, M2
Yang, H7
Hossain, M1
Montesinos, P2
Recher, C1
Vives, S1
Zarzycka, E1
Wang, J1
Bertani, G1
Heuser, M1
Calado, RT1
Schuh, AC2
Yeh, SP1
Daigle, SR1
Hui, J1
Pandya, SS1
Gianolio, DA2
de Botton, S9
Döhner, H4
Liu, C1
Zou, W1
Nie, D1
Li, S1
Duan, C1
Zhou, M1
Lai, P1
Yang, S1
Ji, S1
Li, Y1
Mei, M1
Bao, S1
Jin, Y1
Pan, J1
Killock, D1
Gil-Sierra, MD1
Briceño-Casado, MP1
Sierra-Sanchez, JF1
Goodman, AM1
Mohyuddin, GR1
Prasad, V1
Reinbold, R1
Hvinden, IC1
Rabe, P1
Herold, RA1
Finch, A1
Wood, J1
Morgan, M1
Staudt, M1
Clifton, IJ1
Armstrong, FA1
McCullagh, JSO1
Redmond, J1
Bardella, C1
Abboud, MI1
Schofield, CJ1
Takahashi, K3
Kucukyurt, S1
Eskazan, AE1
Hosono, N1
DiNardo, CD10
Wei, AH2
Roboz, GJ4
Stein, EM6
Mims, AS4
Prince, GT2
Altman, JK4
Arellano, ML2
Donnellan, W2
Erba, HP3
Mannis, GN3
Pollyea, DA4
Stein, AS4
Uy, GL3
Watts, JM3
Fathi, AT5
Kantarjian, HM6
Tallman, MS5
Choe, S6
Dai, D4
Wang, H5
Zhang, V4
Yen, KE2
Kapsalis, SM3
Hickman, D2
Liu, H7
Agresta, SV2
Wu, B7
Attar, EC4
Stone, RM5
Estey, E2
Karp, JE1
Emadi, A1
Othus, M1
Gale, RP1
Pasquier, F1
Lecuit, M1
Broutin, S1
Saada, S1
Jeanson, A1
Penard-Lacronique, V1
Griffiths, EA1
Carraway, HE1
Chandhok, NS1
Prebet, T1
Stein, E1
Liu, G5
Lemieux, I1
Quek, L1
Konteatis, Z1
Dang, L1
Nicolay, B1
Nejad, P1
Goldwasser, M3
Liu, W1
Marks, K1
Bowden, C2
Biller, SA1
Norsworthy, KJ2
Mulkey, F1
Scott, EC1
Ward, AF1
Przepiorka, D2
Charlab, R2
Dorff, SE2
Deisseroth, A2
Kazandjian, D1
Sridhara, R1
Beaver, JA1
Farrell, AT2
de Claro, RA1
Pazdur, R2
Navada, SC2
Garcia-Manero, G2
OdchimarReissig, R1
Pemmaraju, N1
Alvarado, Y1
Ohanian, MN1
John, RB1
Demakos, EP2
Zbyszewski, PS2
Maniar, M2
Woodman, RC1
Fruchtman, SM2
Silverman, LR3
Zeidner, JF1
Tabata, MM1
Chase, M1
Kwong, BY1
Novoa, RA1
Fernandez-Pol, S1
Jeng, MY1
Dutta, R1
Tan, IT1
Zhang, TY1
Donker, ML1
Ossenkoppele, GJ3
Martelli, MP1
Martino, G1
Cardinali, V1
Falini, B1
Martinelli, G2
Cerchione, C1
Prakash, C3
Ke, A2
Le, K2
Pratz, KW1
Savona, MR1
Winer, ES1
Seet, CS1
McCloskey, JK1
Odenike, O1
Löwenberg, B2
Patel, PA2
Roshal, M1
Frattini, MG2
Lersch, F2
Franovic, A2
Visani, G1
Loscocco, F1
Dennis, M2
Zuffa, E1
Candoni, A1
Sensi, A1
Giannini, B1
Musuraca, G1
Mianulli, AM1
Clavio, M1
Rocchi, M1
Gibellini, D1
Navari, M1
Gilkes, A1
Piccaluga, PP1
Isidori, A1
Frankfurt, O2
Raffoux, E1
Tan, P1
Zeidan, AM1
Gong, J1
Daigle, S1
Winkler, T2
Vyas, P1
Xiao, W1
Miles, LA1
Bowman, RL1
Durani, V1
Tian, HS1
DelGaudio, NL1
Mishra, T1
Zhu, M1
Zhang, Y1
Stump, SE1
Levine, RL1
Cai, SF1
Jiang, X1
Wada, R1
Poland, B1
Kleijn, HJ1
Kapsalis, S1
Pigneux, A2
Collins, R1
Roeten, MSF1
van Meerloo, J1
Kwidama, ZJ1
Ter Huizen, G1
Segerink, WH1
Zweegman, S2
Kaspers, GJL1
Jansen, G1
Cloos, J1
Bolleddula, J1
Burnett, A2
Hills, R1
Thomas, I1
Ariti, C1
Severinsen, MT1
Hemmaway, C1
Greaves, P1
Clark, RE1
Copland, M1
Russell, N1
Wang, F1
Morita, K1
Furudate, K1
Tanaka, T1
Yan, Y1
Patel, KP1
MacBeth, KJ1
Frattini, M1
Matthews, JA1
Little, LD1
Gumbs, C1
Song, X1
Zhang, J1
Thompson, EJ1
Kadia, TM1
Jabbour, E1
Ravandi, F2
Bhalla, KN1
Konopleva, M2
Andrew Futreal, P1
Odchimar-Reissig, R1
Petrone, ME1
Holland, JF2
Swords, R1
Collins, RH1
Foran, JM1
Traer, E1
Stuart, RK1
Slack, JL1
Sekeres, MA2
Willekens, C1
Agresta, S2
Sidaway, P1
Khan, I1
Halasi, M1
Patel, A1
Schultz, R1
Kalakota, N1
Chen, YH1
Aardsma, N1
Liu, L1
Crispino, JD1
Mahmud, N1
Gartel, AL1
Dhillon, S1
Talati, C1
Sweet, K1
Aschenbrenner, DS1
Luo, L1
Hsu, V1
Gudi, R1
Shen, YL1
Sheth, CM1
Williams, GM1
Goldberg, KB1
Tiong, IS1
Advani, AS1
Cooper, B1
Visconte, V1
Elson, P1
Chan, R1
Carew, J1
Wei, W1
Mukherjee, S1
Gerds, A1
Carraway, H1
Nazha, A1
Hamilton, B1
Sobecks, R1
Caimi, P1
Tomlinson, B1
Malek, E1
Little, J1
Miron, A1
Pink, J1
Maciejewski, J1
Unger, A1
Kalaycio, M1
de Lima, M1
Zacher, J1
Vutikullird, A1
Guerra, VA1
DiNardo, C1
Hernandez Burgos, P1
Patel, J1
Chen, A1
Cortes, JE1
Kovarik, ML1
Dickinson, AJ1
Roy, P1
Poonnen, RA1
Fine, JP1
Allbritton, NL1
Greenberg, P1
Raza, A1
Olnes, MJ1
Reddy, P1
Wilhelm, F1
El-Ghany, HM1
El-Saadany, ZA1
Bahaa, NM1
Ibrahim, NY1
Hussien, SM1
Sachs, Z1
LaRue, RS1
Nguyen, HT1
Sachs, K1
Noble, KE1
Mohd Hassan, NA1
Diaz-Flores, E1
Rathe, SK1
Sarver, AL1
Bendall, SC1
Ha, NA1
Diers, MD1
Nolan, GP1
Shannon, KM1
Largaespada, DA1
Mawad, R1
Becker, PS1
Hendrie, P1
Scott, B1
Wood, BL1
Dean, C1
Sandhu, V1
Deeg, HJ1
Walter, R1
Wang, L1
Myint, H1
Singer, JW1
Pagel, JM1
Garcia, JS1
Huang, M1
Medeiros, BC1
Mitchell, BS1
Morgan, G1
Burnett, AK1
Zachée, P1
Dührsen, U1
Dierickx, D1
Müller-Tidow, C1
Sonneveld, P1
Krug, U1
Bone, E1
Flores, N1
Richardson, AF1
Hooftman, L1
Jenkins, C2
Davies, F1
Hewamana, S1
Krige, D1
Pepper, C1
Shi, J1
Wang, E1
Zuber, J1
Rappaport, A1
Taylor, M1
Johns, C1
Lowe, SW1
Vakoc, CR1
Mathisen, MS1
Szer, J1
Bacher, U1
Haferlach, T1
Schoch, C1
Kern, W1
Schnittger, S1
Kien, CL1
Camitta, BM1
Choi, CH1
Kim, HS1
Kweon, OS1
Lee, TB1
You, HJ1
Rha, HS1
Jeong, JH1
Lim, DY1
Min, YD1
Kim, MS1
Chung, MH1
Palma-Carlos, AG1
Palma-Carlos, L1
Lourenço, G1
Loeper, J1
Cottet, J1
Debray, J1
Taylor, GM1
Freeman, CB1
Harris, R1
Hashino, S1
Imamura, M1
Kobayashi, H1
Tanaka, M1
Fukuhara, T1
Fujimoto, H1
Karino, Y1
Yoshida, J1
Sakurada, K1
Matsushima, T1
Miura, K1
Sawa, T1
Takeuchi, T1
Umezawa, H1
Kotlarek-Haus, S1
Eastman, PM1
Schwartz, R1
Schrier, SL1
Walters, TR1
Welland, FH1
Gribble, TJ1
Schwartz, HC1
Takaku, F1
Wada, O1
Sassa, S1
Nakao, K1
Rosa, J1
Beuzard, Y1
Brun, B1
Toulgoat, N1
Cerný, V1
Dimitrov, NV1
Hansz, J1
Toth, MA1
Bartolotta, B1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation[NCT02632708]Phase 1153 participants (Actual)Interventional2015-12-31Active, not recruiting
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation[NCT03173248]Phase 3146 participants (Actual)Interventional2017-06-26Active, not recruiting
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation[NCT02074839]Phase 1291 participants (Anticipated)Interventional2014-03-31Recruiting
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia[NCT01926587]Phase 1/Phase 245 participants (Actual)Interventional2013-08-31Completed
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute [NCT02677922]Phase 1/Phase 2130 participants (Actual)Interventional2016-06-03Active, not recruiting
Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS[NCT00854646]Phase 122 participants (Actual)Interventional2008-10-31Completed
A Phase I, First in Human, Open-label Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia[NCT03957915]Early Phase 134 participants (Anticipated)Interventional2020-05-29Recruiting
Efficacy and Safety of Ambulatory Low-dose Venetoclax and Azacitidne as First Line Therapy in Newly Diagnosed AML: a Pilot Study[NCT05048615]Phase 215 participants (Actual)Interventional2021-07-26Completed
Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine[NCT01928537]Phase 367 participants (Actual)Interventional2013-08-31Completed
A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk[NCT00906334]Phase 214 participants (Actual)Interventional2009-05-31Completed
A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma[NCT00689000]Phase 1/Phase 257 participants (Actual)Interventional2006-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Event-Free Survival (EFS)

EFS was defined as the time from randomization until treatment failure, relapse from remission, or death from any cause, whichever occurs first. Treatment failure was defined as failure to achieve complete remission (CR) by Week 24. CR: Bone marrow blasts <5% and no Auer rods; absence of extramedullary disease; Absolute neutrophil count (ANC) ≥1.0 × 10^9 per litre (10^9/L) (1000 per microlitre [1000/μL]); platelet count ≥100 × 10^9/L (100,000/μL); independence of red blood cell transfusions. Participants who had an EFS event (relapse or death) after, 2 or more missing disease assessments were censored at the last adequate disease assessment documenting no relapse before the missing assessments. The reported data represents the Kaplan-Meier median value. (NCT03173248)
Timeframe: Up to Week 24

Interventionmonths (Median)
AG-120 + Azacitidine0.03
Placebo + Azacitidine0.03

AUC (0-24)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)

AUC0-24: Area under the plasma concentration-time curve from time zero to 24 hours, calculated using the linear trapezoid rule. (NCT02677922)
Timeframe: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2

Intervention(h*ng/mL) (Mean)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA285864.2637

AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 2 (Randomized Stage)

Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule. (NCT02677922)
Timeframe: Pre-dose, 2, 3, 4, 6, and 8 hours post dose (± 10 minutes) on day 1 of cycle 2

Intervention(h*ng/mL) (Mean)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA100302.8231

Change From Baseline in Health Utility Indices of the EQ-5D-5L: Phase 2 (Randomized Stage)

The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values. (NCT02677922)
Timeframe: Baseline and Day 1 Cycle 5

InterventionScore on a scale (Mean)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA0.04
Phase 2 Randomized Stage: AZA Monotherapy0.02

Change From Baseline in Visual Analogue Scale (VAS) Scores of the EQ-5D-5L: Phase 2 (Randomized Stage)

"The European Quality of Life 5D-5L (EQ-5D-5L) instrument has a respondent's self-rated today's health scale which is recorded on a VAS with endpoints labeled the best health you can imagine and the worst health you can imagine. The scale is numbered from 0 to 100 with 0 corresponding to the worst imaginable health state and 100 corresponding to the best imaginable health state. A high score represents a better level of QoL. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values." (NCT02677922)
Timeframe: Baseline and Day 1 Cycle 5

InterventionScore on a scale (Mean)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA13.00
Phase 2 Randomized Stage: AZA Monotherapy1.65

Cmax- Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)

Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. (NCT02677922)
Timeframe: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2

Intervention(ng/mL) (Mean)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA15965.0

Complete Remission Rate: Phase 2 (Randomized Stage)

The percent of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. (NCT02677922)
Timeframe: From first dose up to approximately 26 months

InterventionPercent of Participants (Number)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA54.4
Phase 2 Randomized Stage: AZA Monotherapy12.1

Duration of Response: Phase 2 (Randomized Stage)

The time from first documented CR/CRi/CRp/PR/MLFS to documented morphologic relapse, progression, or death due to any cause, whichever occurred first. CR and MLFS are defined as <5% blasts in a BM aspirate sample with marrow spicules + a count of ≥200 nucleated cells with no blasts with Auer rods + no extramedullary disease. CR must also include: ANC ≥ 1,000/μL, Platelet count ≥100,000/μL, + independent of red cell transfusions for ≥1 week before assessment. CRi is all criteria of CR except ANC. CRp is all criteria of CR except platelet count. PR is defined as all hematologic criteria of CR with >50% decrease in BM blasts to 5%-25%. Relapse is defined as reappearance of ≥ 5% blasts in the BM not attributable to other cause or development of extramedullary disease. Progression is defined as > 50% increase of BM blast count from baseline to ≥ 20% or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10,000/μL or development of new extramedullary disease. (NCT02677922)
Timeframe: From first dose up to approximately 26 months

InterventionMonths (Median)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA24.1
Phase 2 Randomized Stage: AZA Monotherapy9.9

Event-free Survival (EFS): Phase 2 (Randomized Stage)

Event-Free Survival is the time from date of randomization to the date of documented morphologic relapse, progression, or death from any cause, whichever occurs first. Morphologic Relapse is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. Progression is defined as a > 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with > 70% BM blasts at baseline or the development of new extramedullary disease. (NCT02677922)
Timeframe: From randomization to the date of documented relapse, progression, or death due to any cause, whichever occurs first (up to approximately 26 months)

InterventionMonths (Median)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA15.9
Phase 2 Randomized Stage: AZA Monotherapy11.9

Hematologic Improvement (HI) Rate: Phase 2 (Randomized Stage)

The percent of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by ≥ 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of ≥ 30 X 10^9/L for participants starting with > 20 X and an increase from < 20 X 10^9/L to > 20 X 10^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase > 0.5 X 10^9/L. (NCT02677922)
Timeframe: From first dose up to approximately 26 months

InterventionPercent of Participants (Number)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA70.6
Phase 2 Randomized Stage: AZA Monotherapy57.6

One Year Survival Rate: Phase 2 (Randomized Stage)

The percent of participants alive at 1 year from randomization (NCT02677922)
Timeframe: From randomization to 1 year after randomization

InterventionPercent of Participants (Number)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA72.2
Phase 2 Randomized Stage: AZA Monotherapy69.6

Overall Response Rate: Phase 1B (Dose Finding and Expansion Stage)

Percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present). (NCT02677922)
Timeframe: From first dose up to approximately 13 months

InterventionPercent of Participants (Number)
Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA66.7
Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA66.7
Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA100
Phase 1b Expansion Stage: AG-120 (500mg) + AZA68.8

Overall Response Rate: Phase 2 (Randomized Stage)

The percent of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria as assessed by investigator. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present). (NCT02677922)
Timeframe: From first dose up to approximately 26 months

InterventionPercent of Participants (Number)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA73.5
Phase 2 Randomized Stage: AZA Monotherapy36.4

Overall Survival: Phase 2 (Randomized Stage)

Overall survival (OS) is defined as time from randomization to death due to any cause. (NCT02677922)
Timeframe: From randomization to date of death (up to approximately 26 months)

InterventionMonths (Median)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA22.0
Phase 2 Randomized Stage: AZA Monotherapy22.3

Sponsor Derived CR and CRh: Phase 1B (Dose Finding and Expansion Stage)

The percent of participants with morphologic complete remission (CR) and morphologic complete remission with partial hematologic recovery (CRh) based on laboratory data. CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease. Plus, all the following conditions should be met: ANC ≥ 1 x 109/L (1,000/μL), platelet count ≥ 100 x 109/L (100,000/μL), independent of red cell transfusions for ≥ 1 week immediately before each response assessment. CRh is defined as less than 5% blasts in a BM aspirate sample with marrow spicules plus ANC > 500 x 109/L (1,000/μL) & Platelet count > 50 x 109/L (100,000/μL). CRh is defined as Response of bone marrow blast <5% with absolute neutrophil count (ANC) > 0.5 × 10^9/L and platelet > 50 × 10^9/L. (NCT02677922)
Timeframe: From first dose up to approximately 13 months

InterventionPercent of Participants (Number)
Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA66.7
Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA66.7
Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA71.4
Phase 1b Expansion Stage: AG-120 (500mg) + AZA62.5

The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)

Dose-limiting toxicities (DLTs) are defined as an event that constitute a change from baseline irrespective of outcome and determined by the investigator to be related to treatment. The DLT-evaluable participants were defined as participants who took at least 1 dose of study drug in the Phase 1b Dose-Finding Stage and either had a DLT during Cycle 1 (regardless of amount of study drug exposure), or had no DLT and completed at least 75% of AG-120 or AG-221 doses (21 out of 28 days) and a minimum of 5 doses of AZA, at least 50% of the planned combination doses for AG-120 or AG-221 and AZA administered together (in the same day for 4 out of 7 days) in the first 28 days from C1D1, and were also considered by the Clinical Study Team to have sufficient safety data available to conclude that a DLT did not occur during Cycle 1. (NCT02677922)
Timeframe: From first dose to 28 days after first dose

InterventionParticipants (Count of Participants)
Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA0
Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA0
Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA0

Time to Response: Phase 2 (Randomized Stage)

Time from first dose of study drug to first documented MLFS/CR/CRi/CRp/PR according to modified IWG AML response criteria. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present). (NCT02677922)
Timeframe: From first dose to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 26 months)

InterventionMonths (Mean)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA3.05
Phase 2 Randomized Stage: AZA Monotherapy3.42

Tmax- Time of Maximum Observed Plasma Concentration: Phase 2 (Randomized Stage)

Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data. (NCT02677922)
Timeframe: Pre-dose, 2, 3, 4, 6, 8, and 24 hours post dose (± 10 minutes) on day 1 of cycle 2

Intervention(h) (Median)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA2.5333

AUC (0-8)- Area Under the Plasma Concentration-Time Curve: Phase 1B (Expansion Stage)

Area under the plasma concentration-time curve from time zero to 8 hours, calculated using the linear trapezoid rule. (NCT02677922)
Timeframe: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2

Intervention(h*ng/mL) (Mean)
CYCLE 1 DAY 1CYCLE 2 DAY 1
Phase 1b Expansion Stage: AG-120 (500mg) + AZA31952.446544291.5504

Change From Baseline in Health-related Quality-of-Life Domain Scores of the EORTC QLQ-C30: Phase 2 (Randomized Stage)

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values. EORTC QLQ-C30 is assessed prior to dosing and prior to interaction with study personnel. (NCT02677922)
Timeframe: Baseline and Day 1 Cycle 5

,
InterventionScore on a scale (Mean)
Global QoLPhysical functioningRole functioningCognitive functioningEmotional functioningSocial functioningFatigueNausea and vomitingPainDyspneaInsomniaAppetite lossConstipationDiarrheaFinancial difficulties
Phase 2 Randomized Stage: AG-221 (100mg) + AZA12.21.9-0.6-4.87.7-6.5-17.5-6.0-13.1-27.4-6.0-7.16.0-7.18.3
Phase 2 Randomized Stage: AZA Monotherapy4.96.71.04.98.86.9-8.51.0-4.9-9.8-13.7-5.9-9.8-5.9-2.0

Cmax- Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)

Cmax: Maximum observed plasma concentration, obtained directly from the observed concentration versus time data (NCT02677922)
Timeframe: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2

Intervention(ng/mL) (Mean)
CYCLE 1 DAY 1CYCLE 2 DAY 1
Phase 1b Expansion Stage: AG-120 (500mg) + AZA6058.06340.7

The Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)

The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death. (NCT02677922)
Timeframe: From first dose to 28 days after last dose (up to approximately 13 months)

,,,
InterventionParticipants (Count of Participants)
Participants with at Least One TEAEParticipants with at Least One TEAE Related to Study Drug(s)Participants with at Least One Grade 3-4 TEAEParticipants with at least One Grade 3-4 TEAE Related to Study Drug(s)Participants with at Least One Grade 5 TEAEParticipants with at Least One Grade 5 TEAE Related to Study Drug(s)Participants with at Least One Serious TEAEParticipants with at Least One Serious TEAE Related to Study Drug(s)Participants with at Least One TEAE Leading to Discontinuation of Study Drug(s)Participants with at Least One Study Drug Related TEAE Leading to Discontinuation of Study DrugParticipants with at Least One TEAE Leading to Dose Reduction of Study Drug(s)Participants with at Least One TEAE Leading to Dose Interruption of Study Drug(s)Participants with at Least One Study Drug(s) Related TEAE Leading to Study Drug Dose ReductionParticipants with at Least One Study Drug(s) Related TEAE Leading to Study Drug Dose Interruption
Phase 1b Dose-finding Stage: AG-120 (500mg) + AZA77741041102212
Phase 1b Dose-finding Stage: AG-221 (100mg) + AZA33320030101301
Phase 1b Dose-finding Stage: AG-221 (200mg) + AZA33321021001312
Phase 1b Expansion Stage: AG-120 (500mg) + AZA16161510201154151158

The Number of Participants Experiencing Adverse Events: Phase 2 (Randomized Stage)

The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or constitutes an important medical event. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). Treatment-emergent adverse events (TEAE) was defined as events that began on or after the start of study drug through 28 days after the last study treatment. The severity/intensity of AEs were graded based upon the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03) where Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death. (NCT02677922)
Timeframe: From first dose to 28 days after last dose (up to approximately 26 months)

,
InterventionParticipants (Count of Participants)
Participants with at Least One TEAEParticipants with at Least One TEAE Related to Study Drug(s)Participants with at Least One Grade 3-4 TEAEParticipants with at least One Grade 3-4 TEAE Related to Study Drug(s)Participants with at Least One Grade 5 TEAEParticipants with at Least One Grade 5 TEAE Related to Study Drug(s)Participants with at Least One Serious TEAEParticipants with at Least One Serious TEAE Related to Study Drug(s)
Phase 2 Randomized Stage: AG-221 (100mg) + AZA686268501506429
Phase 2 Randomized Stage: AZA Monotherapy32263120202514

Tmax- Time of Maximum Observed Plasma Concentration: Phase 1B (Expansion Stage)

Tmax: Time of maximum observed plasma concentration, obtained directly from the observed concentration versus time data. (NCT02677922)
Timeframe: Pre-dose, 0.5, 2, 3, 4, 6, 8 hours post dose (± 10 minutes) on day 1 of cycle 1 and 2

Intervention(h) (Median)
CYCLE 1 DAY 1CYCLE 2 DAY 1
Phase 1b Expansion Stage: AG-120 (500mg) + AZA3.00002.5000

Reviews

15 reviews available for glycine and Leukemia, Myeloid, Acute

ArticleYear
New drugs approved for acute myeloid leukaemia in 2018.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:12

    Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; C

2019
[New therapeutic agents for acute myeloid leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2019, Volume: 60, Issue:9

    Topics: Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Drug Approval; Flavonoids; G

2019
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
    Leukemia, 2020, Volume: 34, Issue:3

    Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorub

2020
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
    Leukemia research, 2020, Volume: 91

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo C

2020
Evaluating ivosidenib for the treatment of acute myeloid leukemia.
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:18

    Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Glycine; H

2020
Enasidenib and ivosidenib in AML.
    Minerva medica, 2020, Volume: 111, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Cell Differentiation; Clinical Trials as Topic; Glutarates; G

2020
Ivosidenib: First Global Approval.
    Drugs, 2018, Volume: 78, Issue:14

    Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Approval; Enzyme Inhibitors; Epigenesis, Genetic

2018
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
    Leukemia research, 2018, Volume: 73

    Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female

2018
New drugs creating new challenges in acute myeloid leukemia.
    Genes, chromosomes & cancer, 2019, Volume: 58, Issue:12

    Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab;

2019
Venetoclax-based therapies for acute myeloid leukemia.
    Best practice & research. Clinical haematology, 2019, Volume: 32, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Comp

2019
Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:3

    Topics: Adult; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Mutation; Myocarditis; Pyridines; Recurren

2020
Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:2

    Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Glycine; Humans; Hydroxamic Acids; Leukem

2014
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins

2015
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins

2015
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins

2015
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins

2015
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins

2015
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins

2015
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins

2015
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins

2015
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Hematological oncology, 2015, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins

2015
Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.
    Future oncology (London, England), 2012, Volume: 8, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aminopeptidases; Antineoplastic Agents; Antineoplasti

2012
The prevalent predicament of relapsed acute myeloid leukemia.
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Adenine Nucleotides; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Arabinonucleos

2012

Trials

16 trials available for glycine and Leukemia, Myeloid, Acute

ArticleYear
Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
    Clinical pharmacology in drug development, 2022, Volume: 11, Issue:4

    Topics: Adult; Aminopyridines; Antineoplastic Agents; Consolidation Chemotherapy; Glycine; Humans; Isocitrat

2022
Ivosidenib and Azacitidine in
    The New England journal of medicine, 2022, 04-21, Volume: 386, Issue:16

    Topics: Antineoplastic Agents; Azacitidine; Febrile Neutropenia; Glycine; Humans; Isocitrate Dehydrogenase;

2022
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
    Blood, 2020, 02-13, Volume: 135, Issue:7

    Topics: Aged; Aged, 80 and over; Blood Transfusion; Female; Glycine; Humans; Isocitrate Dehydrogenase; Leuke

2020
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
    Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:5

    Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Mo

2020
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
    Leukemia research, 2020, Volume: 94

    Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Glycine; Humans; Leukemia, Myelogenous, Chronic

2020
Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies.
    American journal of hematology, 2020, Volume: 95, Issue:11

    Topics: Aged, 80 and over; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Blood, 2021, 04-01, Volume: 137, Issue:13

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Female; Glycine; Humans; Isocitrate Dehydrogenas

2021
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 01-01, Volume: 39, Issue:1

    Topics: Aged; Aged, 80 and over; Apoptosis; Azacitidine; Drug Therapy, Combination; Enzyme Inhibitors; Femal

2021
Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
    Clinical and translational science, 2021, Volume: 14, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under

2021
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    British journal of haematology, 2021, Volume: 194, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo

2021
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Leukemia research, 2018, Volume: 64

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Dru

2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    The New England journal of medicine, 2018, Jun-21, Volume: 378, Issue:25

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cell Count; Dose-Response Relation

2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    The New England journal of medicine, 2018, Jun-21, Volume: 378, Issue:25

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cell Count; Dose-Response Relation

2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    The New England journal of medicine, 2018, Jun-21, Volume: 378, Issue:25

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cell Count; Dose-Response Relation

2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    The New England journal of medicine, 2018, Jun-21, Volume: 378, Issue:25

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cell Count; Dose-Response Relation

2018
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 07-15, Volume: 25, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resis

2019
Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
    European journal of clinical pharmacology, 2019, Volume: 75, Issue:8

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Asian People; Cross-Over Studi

2019
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    British journal of haematology, 2016, Volume: 172, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; De

2016
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-01, Volume: 28, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Aminopeptidases; Female; Glycine; Humans; Hydroxamic Acids; Leukemia

2010

Other Studies

48 other studies available for glycine and Leukemia, Myeloid, Acute

ArticleYear
What to use to treat AML: the role of emerging therapies.
    Hematology. American Society of Hematology. Education Program, 2021, 12-10, Volume: 2021, Issue:1

    Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Appro

2021
Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML.
    Cell metabolism, 2022, 06-07, Volume: 34, Issue:6

    Topics: Animals; Epigenesis, Genetic; Glycine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, M

2022
Ivosidenib Boosts OS with Azacitidine in AML.
    Cancer discovery, 2022, 07-06, Volume: 12, Issue:7

    Topics: Azacitidine; Glycine; Humans; Leukemia, Myeloid, Acute; Pyridines

2022
Ivosidenib combination improves OS.
    Nature reviews. Clinical oncology, 2022, Volume: 19, Issue:7

    Topics: Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines

2022
Ivosidenib and Azacitidine in IDH1-Mutated AML.
    The New England journal of medicine, 2022, 06-30, Volume: 386, Issue:26

    Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines

2022
Ivosidenib and Azacitidine in IDH1-Mutated AML.
    The New England journal of medicine, 2022, 06-30, Volume: 386, Issue:26

    Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines

2022
Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
    The New England journal of medicine, 2022, 06-30, Volume: 386, Issue:26

    Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines

2022
Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
    Nature communications, 2022, 08-15, Volume: 13, Issue:1

    Topics: Drug Resistance, Neoplasm; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Muta

2022
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
    Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:8

    Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridine

2023
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
    Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:8

    Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridine

2023
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
    Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:8

    Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridine

2023
Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
    Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:8

    Topics: Azacitidine; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridine

2023
How I treat acute myeloid leukemia in the era of new drugs.
    Blood, 2020, 01-09, Volume: 135, Issue:2

    Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bi

2020
Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Enzyme Inhibitors; Epigenesis, Genetic; Glycine; Humans; Isocitr

2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
    Blood advances, 2020, 05-12, Volume: 4, Issue:9

    Topics: Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines; Recurrence

2020
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-15, Volume: 26, Issue:16

    Topics: Aminopyridines; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyrid

2020
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-15, Volume: 26, Issue:16

    Topics: Aminopyridines; Cell Differentiation; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid,

2020
Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
    Journal of cutaneous pathology, 2020, Volume: 47, Issue:11

    Topics: Aged; Antineoplastic Agents; Diagnosis, Differential; Glycine; Humans; Immunohistochemistry; Isocitr

2020
Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:5

    Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Computer Simulation; Cytochrome P-450

2020
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML.
    Blood advances, 2020, 10-27, Volume: 4, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Glycine; Humans; Hydroxamic Acids;

2020
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.
    Blood advances, 2020, 12-08, Volume: 4, Issue:23

    Topics: Clone Cells; Glycine; Humans; Isocitrate Dehydrogenase; Janus Kinase 2; Leukemia, Myeloid, Acute; Py

2020
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
    Leukemia, 2021, Volume: 35, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Fo

2021
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Cells, 2021, 03-17, Volume: 10, Issue:3

    Topics: Boron Compounds; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycine; Humans; Leukemia,

2021
PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
    CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:6

    Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Caco-2 Cells; Cytochrome P-450 CYP3A

2021
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
    Nature communications, 2021, 05-10, Volume: 12, Issue:1

    Topics: Aged; Aminopyridines; Antineoplastic Agents; CCAAT-Enhancer-Binding Proteins; Core Binding Factor Al

2021
Ivosidenib effective in IDH1-mutant AML.
    Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:8

    Topics: Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Pyridines

2018
Ivosidenib Deemed Safe, Effective in AML.
    Cancer discovery, 2018, Volume: 8, Issue:8

    Topics: Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines

2018
FOXM1 contributes to treatment failure in acute myeloid leukemia.
    JCI insight, 2018, 08-09, Volume: 3, Issue:15

    Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cell Line, Tumor; Ce

2018
First Drug Approved for Patients with Refractory AML and Mutation in the IDH1 Gene.
    The American journal of nursing, 2018, Volume: 118, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Antineoplastic Agents; Female; Glycine; Humans;

2018
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 06-01, Volume: 25, Issue:11

    Topics: Antineoplastic Agents; Drug Approval; Enzyme Inhibitors; Glycine; Humans; Isocitrate Dehydrogenase;

2019
Response of single leukemic cells to peptidase inhibitor therapy across time and dose using a microfluidic device.
    Integrative biology : quantitative biosciences from nano to macro, 2014, Volume: 6, Issue:2

    Topics: Cell Survival; Dose-Response Relationship, Drug; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloi

2014
Stromal cell derived factor-1 (CXCL12) chemokine gene variant in myeloid leukemias.
    Clinical laboratory, 2014, Volume: 60, Issue:5

    Topics: 3' Untranslated Regions; Adolescent; Adult; Aged; Alanine; Case-Control Studies; Chemokine CXCL12; F

2014
NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
    Blood, 2014, Nov-20, Volume: 124, Issue:22

    Topics: Amino Acid Substitution; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Disease Model

2014
Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Apr-15, Volume: 22, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Line, Tumor; Cell Survival; Cytoplasm; Flow

2016
Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.
    Leukemia research, 2011, Volume: 35, Issue:5

    Topics: Adult; Aminopeptidases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell

2011
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
    Oncogene, 2013, Feb-14, Volume: 32, Issue:7

    Topics: Amino Acid Substitution; Animals; Aspartic Acid; Cell Proliferation; Disease Models, Animal; Genes,

2013
Implications of NRAS mutations in AML: a study of 2502 patients.
    Blood, 2006, May-15, Volume: 107, Issue:10

    Topics: Amino Acid Substitution; Asparagine; Chromosome Inversion; Codon; Gene Frequency; Genes, ras; Glycin

2006
Increased whole-body protein turnover in sick children with newly diagnosed leukemia or lymphoma.
    Cancer research, 1983, Volume: 43, Issue:11

    Topics: Ammonia; Glycine; Humans; Kinetics; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Nitrogen

1983
Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines.
    Molecules and cells, 2000, Feb-29, Volume: 10, Issue:1

    Topics: Alkynes; Antineoplastic Agents; Camptothecin; Cell Survival; Cisplatin; Daunorubicin; Dose-Response

2000
[The effect of cyclophosphamide on haem synthesis in acute myeloblastic leukaemias (author's transl)].
    Sangre, 1975, Volume: 20, Issue:1

    Topics: Aminolevulinic Acid; Anemia, Sideroblastic; Coproporphyrins; Cyclophosphamide; Erythrocytes; Glycine

1975
[Letter: Amino acids and leukemias].
    La Nouvelle presse medicale, 1975, Jan-04, Volume: 4, Issue:1

    Topics: Amino Acids; Cystine; Glycine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Tryptophan

1975
Response of remission lymphocytes to autochthonous leukaemic myeloblasts.
    British journal of cancer, 1976, Volume: 33, Issue:5

    Topics: Antigens; Cell Membrane; Glycine; Humans; Leukemia, Myeloid, Acute; Lymphocyte Activation; Lymphocyt

1976
[Allogeneic bone marrow transplantation after the treatment of alpha-IFN and high-dose SNMC in two cases of acute myeloblastic leukemia with post-transfusional non-A, non-B hepatitis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1989, Volume: 30, Issue:11

    Topics: Adult; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Glycine; G

1989
Effects of enzyme inhibitors in inhibiting the growth and inducing the differentiation of human promyelocytic leukemia cells, HL-60.
    The Journal of antibiotics, 1986, Volume: 39, Issue:5

    Topics: Anti-Bacterial Agents; Cell Differentiation; Cell Line; Enzyme Inhibitors; Glycine; Guanidines; Huma

1986
[Behavior of aminopeptidase activity in human leukemic leukocytes].
    Folia haematologica (Leipzig, Germany : 1928), 1971, Volume: 96, Issue:3

    Topics: Acyltransferases; Adolescent; Adult; Aged; Aminopeptidases; Aspartic Acid; Child; Clinical Enzyme Te

1971
Distinctions between idiopathic ineffective erythropoiesis and di Guglielmo's disease: clinical and biochemical differences.
    Blood, 1972, Volume: 40, Issue:4

    Topics: 5-Aminolevulinate Synthetase; Adult; Aged; Anemia, Hemolytic; Blood Cell Count; Blood Platelets; Bon

1972
Biosynthesis of heme in leukemic leukocytes.
    Cancer, 1967, Volume: 20, Issue:7

    Topics: Adult; Animals; Glycine; Heme; Humans; Iron Isotopes; Leukemia; Leukemia, Lymphoid; Leukemia, Monocy

1967
Heme synthesis in normal and leukemic leukocytes.
    Cancer research, 1968, Volume: 28, Issue:7

    Topics: Carbon Isotopes; Glycine; Heme; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, M

1968
Evidence of various types of synthesis of human gamma chains of haemoglobin in acquired haematological disorders.
    Nature: New biology, 1971, Sep-22, Volume: 233, Issue:38

    Topics: Alanine; Anemia; Anemia, Sideroblastic; Blood Cell Count; Child, Preschool; Chromatography; Chromato

1971
Preliminary clinical trial with a purine analogue butocine.
    Neoplasma, 1971, Volume: 18, Issue:5

    Topics: Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Bronchogenic; Drug Tolerance; Glycine; Humans

1971
Serine and aspartic acid metabolism in leukemic leukocytes: correlation to effectiveness of therapy.
    Blood, 1971, Volume: 38, Issue:5

    Topics: Adult; Aged; Aspartic Acid; Blood Proteins; Carbon Dioxide; Carbon Isotopes; Female; Glycine; Humans

1971